title: Mizoribine in combination therapy with tacrolimus for living donor renal transplantation: analysis of a nationwide study in Japan.
authors.affiliation: Department of Urology, Sakai Hospital, Kinki University, Sakai City, Osaka, Japan. akiyama@sakai.med.kindai.ac.jp
authors.forename: T
authors.initials: T
authors.lastname: Akiyama
authors.forename: H
authors.initials: H
authors.lastname: Okazaki
authors.forename: K
authors.initials: K
authors.lastname: Takahashi
authors.forename: A
authors.initials: A
authors.lastname: Hasegawa
authors.forename: K
authors.initials: K
authors.lastname: Tanabe
authors.forename: K
authors.initials: K
authors.lastname: Uchida
authors.forename: S
authors.initials: S
authors.lastname: Takahara
authors.forename: H
authors.initials: H
authors.lastname: Toma
mesh_terms: D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control*; D006085:Graft Survival / Q000187:drug effects / Q000276:immunology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015994:Incidence; D007239:Infections / Q000453:epidemiology; D007564:Japan; D007677:Kidney Function Tests; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality; D019520:Living Donors; D011183:Postoperative Complications / Q000453:epidemiology; D012263:Ribonucleosides / Q000009:adverse effects / Q000627:therapeutic use*; D016019:Survival Analysis; D016559:Tacrolimus / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D007166:Immunosuppressive Agents; D012263:Ribonucleosides; C010052:mizoribine; D016559:Tacrolimus